GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives
This article was originally published in The Pink Sheet Daily
Executive Summary
The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.
You may also be interested in...
GPHA President Jaeger Keynotes Lehman Investment Conference March 31
GPHA priorities of follow-on biologics, “authorized” generics are likely to be highlighted. CMS’ Trysla gives opening address at March 30-April 1 investment conference in Miami Beach.
GPHA President Jaeger Keynotes Lehman Investment Conference March 31
GPHA priorities of follow-on biologics, “authorized” generics are likely to be highlighted. CMS’ Trysla gives opening address at March 30-April 1 investment conference in Miami Beach.
FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.